Your session is about to expire
← Back to Search
Pirtobrutinib + Venetoclax for Chronic Lymphocytic Leukemia
Study Summary
This trial studies how two drugs (pirtobrutinib and venetoclax) can treat Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and measure a blood test (minimal residual disease) to guide treatment length.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any uncontrolled illnesses or serious heart, infection, or mental health issues.I do not have another cancer that needs treatment or shortens my life expectancy to 2 years or less.My condition has progressed to a more aggressive form.I am able to care for myself and perform daily activities.I am currently taking specific medications.I am 18 years old or older.I have not received any treatment for CLL/SLL.I have not received a live vaccine in the last 28 days.I have been diagnosed with CLL or SLL based on specific health criteria.My CLL/SLL cancer has spread to my brain or spinal cord.I have SLL with measurable B-cell clone in my blood or bone marrow.I meet at least one required condition for treatment.
- Group 1: Treatment (pirtobrutinib and venetoclax)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings remaining for prospective participants?
"According to the information on clinicaltrials.gov, this clinical trial is not currently recruiting patients. It was first put up for public view on January 17th 2023 and last revised December 28th 2022. At present, there are 1,491 other trials actively searching for participants."
Has the FDA officially endorsed pirtobrutinib and venetoclax for therapeutic purposes?
"The safety of the combination regimen (pirtobrutinib and venetoclax) was given a rating of 2, as this is only a phase two trial; thus, there is some data for health protection but none that prove efficacy."
Share this study with friends
Copy Link
Messenger